# Trade Mark Journal No.2025/044 31 October 2025

## WO0000001881271 (5,35,44)

Office of origin: United States of America

Date of International Registration:21 May 2025
Date of designation in the UK: 21 May 2025

The mark consists of a stylized sun with three partial rays extending inward.

International priority date claimed: 18 December 2024 (United States of America) (98909905)
International priority date claimed: 18 December 2024 (United States of America) (98909908)

Class 5
  Pharmaceutical preparations and substances for the treatment of edema, namely hereditary angioedema; pharmaceuticals for the treatment of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders.
Class 35
  Collecting data and information on autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders for treatment and diagnostic purposes.
Class 44
  Medical services; medical information services; providing medical and healthcare information for healthcare professionals, caregivers, patients, and providers in the fields of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders via a web site; medical consulting services in the field of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders; healthcare services, namely, providing medical and healthcare information in the field of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune lymphoproliferative, and rare diseases and disorders via an online database; providing medical and healthcare information concerning the screening, diagnosis, and treatment of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders.

Ionis Pharmaceuticals, Inc.

Representative: Brian J. Focarino Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, IP Docketing Department, Washington DC 20004, UNITED STATES OF AMERICA